Post 1:
This summer we are thrilled to open our doors and welcome in 5 interns to join our Synthegoat herd. 

Emerson Parker joined as a Chemistry Development Intern, Leo Liao joined as a Software Engineering Intern, Ruth Stirrup joined as a Operations Engineering Intern, and Zachary Fung and Izzy Ruiz joined as Commercial Enablement Interns. 

With this program we are excited not only to share our knowledge and training with those aiming to break into the biotech field, but also to bring in fresh ideas and perspectives for us to learn from as well.

--- POST ---

Post 2:
Earlier in June we welcomed our newest addition to the team, Jack Herrera, as a Senior Mechanical Engineer! 

Jack joined our Hardware & Research team, and we are so excited to see all that he will do as our newest Synthegoat. Please join us in giving him a big welcome.

--- POST ---

Post 3:
ğŸš¨ Mark your calendars! ğŸš¨

Join us at the EMBO Workshop in beautiful Sorrento, Italy, November 2nd-5th. Synthego is proud to sponsor this premier event, bringing together leading minds in CRISPR research and gene editing.

This is your chance to connect with key opinion leaders (KOLs), discuss cutting-edge advancements, and explore opportunities that are shaping the future of the field.

â³ Don't wait! Registration closes June 30th. Secure your spot today and be part of the conversation thatâ€™s driving innovation in gene editing.

ğŸ‘‰ Register now and learn more about the event here: https://lnkd.in/dv-49wdM

--- POST ---

Post 4:
Today, we honor the strength and resilience of the millions living with sickle cell disease (SCD) around the world. This day is not only about raising awareness, itâ€™s about recognizing how far weâ€™ve come in the fight to treat and potentially cure this devastating genetic condition.

Incredibly, scientific progress has been made through CRISPR-based therapies. In late 2023, the FDA approved Casgevy (exa-cel), the first CRISPR gene-editing therapy for curing sickle cell disease. This milestone marks a turning point, not just in how we treat SCD, but in how we think about the future of medicine.

Learn more about sickle cell disease and how CRISPR is driving the next era of treatment.

https://lnkd.in/gYPnzvz

--- POST ---

Post 5:
Andrea E. took the stage as a panelist at the 25th American Pharma and Biotech Project, Program, and Portfolio Management Conference, where she shared her insights on leading biotech projects in todayâ€™s fast-moving landscape.

Her key takeaway from the discussion:
â€œChoosing the right approach in Biotech Projects is not a â€˜One size fits all.â€™ Bringing new products to market demands agility and flexibility, but also discipline. Success lies in adaptive project management, supporting cross-functional project teams and stakeholders, and setting realistic expectations, all while maintaining the rigor of regulatory compliance and guidelines.â€

A powerful message for anyone navigating the challenges of innovation and execution.

Congratulations to Andrea for not only contributing her expertise on stage, but also inspiring the next generation of project, program, and portfolio leaders driving progress in pharma and biotech. 

Thank you Andrea for being a leader and rockstar here at Synthego! We appreciate all that you do! ğŸ’š

--- POST ---

Post 6:
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid

The U.S. Court of Appeals has upheld the PTABâ€™s decision in favor of Synthego, confirming that Agilentâ€™s CRISPR gRNA modification patents remain invalidated.  

We see this ruling benefitting the entire CRISPR market, researchers, therapeutic developers and solution providers, by affirming continued access to the chemical modifications that clients rely on to develop world-class therapeutics. 

ğŸ”— Read the full press release: https://lnkd.in/g-vyX-ha

--- POST ---

Post 7:
ğŸ”¬ Synthego at the NIST Genome Editing Consortium Workshop - June 12th
 CRISPR is transforming the future of medicine - and weâ€™re proud to help shape the standards that will drive it forward.

This week, Puzhou Wang, Director of R&D at Synthego, is representing us in the closed NIST Consortium member session, contributing insights on oligonucleotide chemistry and how our technology powers high-quality, safer therapeutic CRISPR solutions.

â€œIâ€™m excited to be attending the NIST Genome Editing Consortium workshop on behalf of Synthego. As a scientist, I get to share my perspective on oligonucleotide chemistry and how we approach making high-quality genome editing tools. Workshops like this are key to establishing standards and driving meaningful benchmark comparisons across the field. Iâ€™m especially looking forward to the scientific conversations and tech talks this week!â€ - Puzhou Wang

ğŸ§¬ As CRISPR-based therapies move rapidly toward the clinic, standardization and benchmarking aren't just helpful - they're essential. We're working with NIST and Consortium partners to lay the foundation for safe, effective, and scalable CRISPR therapeutics.

ğŸ’¡ Want to join the conversation?
 The public session on June 12 is FREE and open to all - a unique chance to hear where the field is heading and how collaborative science is shaping the future of medicine.

ğŸ‘‰ Register here: https://lnkd.in/dxJy_gE9

--- POST ---

Post 8:
Weâ€™ve curated a comprehensive list for you, breaking down the challenges of traditional CRISPR nucleases and provided alternative nuclease solutions that will drive your therapies forward.

Dive into our full breakdown and see how these alternative nuclease solutions will shape the future of your therapeutic development:

https://lnkd.in/dzixA7aA

P.S. - Engineered nucleases offer higher precision, improved safety, and affordable license offerings compared to traditional CRISPR nucleases which we included in our list too. ğŸ‘€

--- POST ---

Post 9:
As we've entered June, the sun is shining and so are our Synthegoats! 

With that in mind we wanted to shine a light on some of those that have hit a milestone anniversary with us in May: 

1 Year: Casey Jowdy and Shannon Mae Magno
2 Years: Dorian E., Angel Mejia Martinez, Jennifer Bennett, Kevin Zamora, and Paulina Hernandez Yanez
3 Years: Annalena Assaiante, Arash Afsarifard, and Qingwen Karen He
4 Years: Bao-An V.

Please help us in giving them all a big round of applause for all their hard work! ğŸ‘

--- POST ---

Post 10:
At Synthego, weâ€™re all about making an impact, and Emily Watkins, our Principal Talent Partner, does just that EVERY DAY! ğŸš€

One of Emilyâ€™s favorite parts of her role? Watching new team members grow, connect, and truly shine âœ¨. She loves seeing individuals sheâ€™s hired not only thrive but even step into leadership roles as hiring managers she gets to partner with in a whole new way. Full-circle moments like these are what make her work so meaningful ğŸ’¼ğŸ’™.

But Emilyâ€™s talents donâ€™t stop at talent acquisition! Outside of work, she unleashes her creativity ğŸ­. With a background in Theater (yes, she majored in it!), Emily loves exploring artistic outlets and finding new ways to spark her imagination.

Emily Watkins, your blend of passion, creativity, and dedication inspires us and reminds us just how special our team is! ğŸ™Œ